267 related articles for article (PubMed ID: 18608348)
1. Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells.
Imataki O; Heike Y; Makiyama H; Iizuka A; Ikarashi Y; Ishida T; Wakasugi H; Takaue Y
Cytotherapy; 2008; 10(5):497-506. PubMed ID: 18608348
[TBL] [Abstract][Full Text] [Related]
2. Efficient ex vivo expansion of Valpha24+ NKT cells derived from G-CSF-mobilized blood cells.
Imataki O; Heike Y; Ishida T; Takaue Y; Ikarashi Y; Yoshida M; Wakasugi H; Kakizoe T
J Immunother; 2006; 29(3):320-7. PubMed ID: 16699375
[TBL] [Abstract][Full Text] [Related]
3. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
[TBL] [Abstract][Full Text] [Related]
4. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ
Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013
[TBL] [Abstract][Full Text] [Related]
5. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide].
Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267
[TBL] [Abstract][Full Text] [Related]
6. Expansion of Valpha24(+)Vbeta11(+) NKT cells from cord blood mononuclear cells using IL-15, IL-7 and Flt3-L depends on monocytes.
Okada H; Nagamura-Inoue T; Mori Y; Takahashi TA
Eur J Immunol; 2006 Jan; 36(1):236-44. PubMed ID: 16380959
[TBL] [Abstract][Full Text] [Related]
7. Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials.
Harada Y; Imataki O; Heike Y; Kawai H; Shimosaka A; Mori S; Kami M; Tanosaki R; Ikarashi Y; Iizuka A; Yoshida M; Wakasugi H; Saito S; Takaue Y; Takei M; Kakizoe T
J Immunother; 2005; 28(4):314-21. PubMed ID: 16000949
[TBL] [Abstract][Full Text] [Related]
8. Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000.
Rogers PR; Matsumoto A; Naidenko O; Kronenberg M; Mikayama T; Kato S
J Immunol Methods; 2004 Feb; 285(2):197-214. PubMed ID: 14980434
[TBL] [Abstract][Full Text] [Related]
9. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.
Osada T; Morse MA; Lyerly HK; Clay TM
Int Immunol; 2005 Sep; 17(9):1143-55. PubMed ID: 16027139
[TBL] [Abstract][Full Text] [Related]
11. CD1d-restricted NKT cell activation enhanced homeostatic proliferation of CD8+ T cells in a manner dependent on IL-4.
Ueda N; Kuki H; Kamimura D; Sawa S; Seino K; Tashiro T; Fushuku K; Taniguchi M; Hirano T; Murakami M
Int Immunol; 2006 Sep; 18(9):1397-404. PubMed ID: 16914507
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
Motohashi S; Ishikawa A; Ishikawa E; Otsuji M; Iizasa T; Hanaoka H; Shimizu N; Horiguchi S; Okamoto Y; Fujii S; Taniguchi M; Fujisawa T; Nakayama T
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6079-86. PubMed ID: 17028247
[TBL] [Abstract][Full Text] [Related]
13. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell maturation by CD11c- T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide.
Ishikawa E; Motohashi S; Ishikawa A; Ito T; Uchida T; Kaneko T; Tanaka Y; Horiguchi S; Okamoto Y; Fujisawa T; Tsuboi K; Taniguchi M; Matsumura A; Nakayama T
Int J Cancer; 2005 Nov; 117(2):265-73. PubMed ID: 15900581
[TBL] [Abstract][Full Text] [Related]
15. Prevention of injury-induced suppression of T-cell immunity by the CD1d/NKT cell-specific ligand alpha-galactosylceramide.
Tulley JM; Palmer JL; Gamelli RL; Faunce DE
Shock; 2008 Feb; 29(2):269-77. PubMed ID: 17693934
[TBL] [Abstract][Full Text] [Related]
16. Polarization of natural killer T cells towards an NKT2 subpopulation occurs after stimulation with alpha-galactosylceramide and rhG-CSF in aplastic anemia.
Wang Y; Hu X; Guo C; Zhang Q; Peng J; Zhang J; Li L; Zhang T; Xu C
Acta Haematol; 2008; 119(3):178-86. PubMed ID: 18535366
[TBL] [Abstract][Full Text] [Related]
17. Activated CD1d-restricted natural killer T cells secrete IL-2: innate help for CD4+CD25+ regulatory T cells?
Jiang S; Game DS; Davies D; Lombardi G; Lechler RI
Eur J Immunol; 2005 Apr; 35(4):1193-200. PubMed ID: 15770696
[TBL] [Abstract][Full Text] [Related]
18. Increased infiltration of CD1d and natural killer T cells in periodontal disease tissues.
Amanuma R; Nakajima T; Yoshie H; Yamazaki K
J Periodontal Res; 2006 Feb; 41(1):73-9. PubMed ID: 16409258
[TBL] [Abstract][Full Text] [Related]
19. A role for natural killer T cells and CD1d molecules in counteracting suppression of hematopoiesis in mice induced by infection with murine cytomegalovirus.
Broxmeyer HE; Dent A; Cooper S; Hangoc G; Wang ZY; Du W; Gervay-Haque J; Sriram V; Renukaradhya GJ; Brutkiewicz RR
Exp Hematol; 2007 Apr; 35(4 Suppl 1):87-93. PubMed ID: 17379092
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T
Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
